Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

• Technology appraisal
• Reference number: TA351
• Published:  22 July 2015